Immunic has announced a 1-for-10 reverse stock split, while C3is also declared a 1-for-7 reverse stock split. These actions are typically taken to increase a company's share price and meet exchange listing requirements.

Immunic, a biopharmaceutical company, has announced the appointment of biopharmaceutical executive Jon Congleton to its board of directors.

Immunic has secured $400 million in financing, setting the stage for the readout of its phase 3 multiple sclerosis (MS) data.

Biopharmaceutical company Immunic has successfully secured $400 million in funding to advance its commercial-stage development projects.

Immunic announced an offering of up to 458.2 million shares of common stock registered for resale by selling stockholders, according to an SEC filing.

Immunic has garnered a new 'Buy' rating from Guggenheim, indicating positive analyst sentiment regarding its lead asset.

Immunic has successfully secured $400 million in funding to support the commercial-stage development of its projects. This capital injection will aid in advancing its pipeline.

Immunic has announced that it has successfully regained compliance with the Nasdaq Stock Market's minimum bid price requirement.

Immunic, a biopharmaceutical company, has successfully secured $400 million in funding to advance its late-stage clinical trials for Multiple Sclerosis (MS) treatments.

Immunic has closed a $200 million private placement to fund late-stage multiple sclerosis trials, securing significant capital for its research and development.